The FDA cleared Travere Therapeutics’ Filspari (sparsentan) for focal segmental glomerulosclerosis (FSGS), handing the company its long-awaited label expansion after a prolonged regulatory path. The approval makes Filspari the first therapy in the US specifically approved for FSGS and opens a major revenue opportunity for the company’s kidney franchise. FSGS is a cause of nephrotic syndrome and can progress to serious kidney impairment. The new indication extends sparsentan’s commercial footprint and reinforces Travere’s focus on rare and difficult-to-treat glomerular diseases, where few targeted options exist. With the FDA’s decision, Travere now has clearer runway for reimbursement and adoption while managing manufacturing and channel readiness for a broader patient population.